Avita have recently added a distribution partner in the UK (in...

Avita have recently added a distribution partner in the UK (in addition to Belgium, Holland, Ireland, Italy, four Nordic countries and in the near-term Spain and Portugal) which implies that after 4.5 year since the last NICE review, they think they have a sufficient body of evidence to be commercially successful with or without the approval of the two authors at the NHS.

While you're active here, can you explain why BARDA has chosen to procure RECELL instead of your preferred technique using some trypsin, kidney dishes and syringes?



The good news for you is once Novosorb gets premarket approval (PMA) for burns (late 2025? reimbursement 2026?), it looks like BARDA will make a procurement agreement with PNV. Hopefully, it looks more like the $7M RECELL order in 2021 rather than the current rapid purchase agreement in case of a mass casualty incident which isn't worth much in terms of revenue unless the worst-case scenario occurs.